{
  "ticker": "AXE",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02968859",
  "id": "02968859",
  "pages": 9,
  "price_sensitive": true,
  "date": "20250714",
  "time": "0827",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250714/pdf/06lrq1tt9h7cqw.pdf",
  "summary": "### **Quarterly Report (Appendix 4C) Summary**  \n\n#### **Key Highlights**  \n- **Quantum Computing (12CQ Project):** Extended collaboration with Queen Mary University of London (QMUL) to advance qubit development, targeting a demonstration by **1HCY26**.  \n- **Biochip Development:**  \n  - Partnered with **Paragraf** to improve graphene-based sensor (gFET) accuracy for blood testing.  \n  - Fabricated **integrated silicon chip** (combining gFET with readout circuitry), a step toward a handheld diagnostic device.  \n- **Advisory Committee:** Formed a high-profile advisory team (Dr. Steven Duvall, Mark Davis, Dr. Anthony Brewer) to guide commercialization.  \n- **Financials:**  \n  - **Cash balance:** **$13.7 million** (no debt).  \n  - **Investments:** Holds shares in **Volatus Capital (CSE:VC)** and **ChemX Materials (ASX:CMX)**.  \n  - Quarterly **operating cash outflow: ($1.8M)**; estimated funding runway: **7.7 quarters**.  \n\n#### **Material Developments**  \n- **Intellectual Property (IP):** Archer retains all IP from collaborations (QMUL, Paragraf).  \n- **Milestone Targets:** Focus on **qubit demonstration (2026)** and **Biochip lab-to-production transition**.  \n\n**Omitted:** Routine operational details, director bios, legal disclaimers.  \n\n**Final Note:** No capital raising, M&A, or material governance changes announced. Focus remains on R&D progress and cash runway.",
  "usage": {
    "prompt_tokens": 5162,
    "completion_tokens": 341,
    "total_tokens": 5503,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-13T22:55:18.519676"
}